Identification of a KRAS mutation in a patient with non-small cell lung cancer treated with chemoradiotherapy and panitumumab

Nicholas G. Zaorsky, Yunguang Sun, Zixuan Wang, Joshua Palmer, Paolo M. Fortina, Charalambos Solomides, Maria Werner-Wasik, Adam P. Dicker, Rita Axelrod, Barbara Campling, Nathaniel Evans, Scott Cowan, Bo Lu

Research output: Contribution to journalArticle

3 Scopus citations

Abstract

RTOG 0839 is a Phase II study of pre-operative chemoradiotherapy with or without panitumumab in potentially operable locally advanced non-small cell lung cancer (NS CLC). The investigational agent, panitumumab, is an anti-epithelial growth factor receptor (EGFR) antibody that improves progression-free survival in chemorefractory metastatic colorectal cancer (mCRC). Recently, both KRAS mutational status (i.e., mutated or not) and subtype (i.e., activating or inactivating) have been shown to be predictive of response to anti-EGFR therapy in mCRC. However, in NS CLC, it is unknown if KRAS mutational status or subtype predict benefit to anti-EGFR therapies because of unique genetic and epigenetic factors unique to each cancer. We present a patient with stage III NS CLC containing a KRAS G12D activating mutation who had a partial pathologic response, with disappearance of a minor KRAS mutant clone. This case suggests possible eradication of the G12D KRAS lung cancer clones by concurrent chemoradiation with panitumumab.

Original languageEnglish (US)
Pages (from-to)883-887
Number of pages5
JournalCancer Biology and Therapy
Volume14
Issue number10
DOIs
StatePublished - Oct 2013

All Science Journal Classification (ASJC) codes

  • Molecular Medicine
  • Oncology
  • Pharmacology
  • Cancer Research

Fingerprint Dive into the research topics of 'Identification of a KRAS mutation in a patient with non-small cell lung cancer treated with chemoradiotherapy and panitumumab'. Together they form a unique fingerprint.

  • Cite this

    Zaorsky, N. G., Sun, Y., Wang, Z., Palmer, J., Fortina, P. M., Solomides, C., Werner-Wasik, M., Dicker, A. P., Axelrod, R., Campling, B., Evans, N., Cowan, S., & Lu, B. (2013). Identification of a KRAS mutation in a patient with non-small cell lung cancer treated with chemoradiotherapy and panitumumab. Cancer Biology and Therapy, 14(10), 883-887. https://doi.org/10.4161/cbt.25942